Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Min Jung Jung"
Filter
Filter
Article type
Keywords
Publication year
Authors
Response
Close layer
Original Article
Thyroid
Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance
Min Jung Jung, Su Kyoung Kwon
Endocrinol Metab. 2014;29(4):536-544.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.536
  • 3,748 View
  • 44 Download
  • 17 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   
Background

Incretin-based therapies are rapidly becoming one of the main glycemic control strategies in diabetes. Considering the large numbers of papillary thyroid carcinomas (PTCs) and possible effects of glucagon-like peptide-1 (GLP-1) on cell proliferation, the expression of GLP-1 receptor (GLP-1R) in PTC is likely to have clinical significance. We performed this study to evaluate the expression of GLP-1R in PTC and the clinical meaning of GLP-1R expression in PTC.

Methods

Fifty-six cases of PTC, four cases of medullary thyroid cancer (MTC), seven cases of nodular hyperplasia and 56 normal thyroid tissue samples were selected for immunostaining for GLP-1R. Clinical parameters were obtained by retrospective review of medical records.

Results

Immunohistochemical staining for GLP-1R showed immunoreactivity in 18 of 56 cases of PTC (32.1%). All four cases of MTC exhibited cytoplasmic GLP-1R expression. Nodular hyperplasia exhibited immunoreactivity in two of seven cases (28.6%). All normal thyroid follicular cells showed negative immunoreactivity. In univariable and multivariable analyses, tumor multifocality was negatively correlated with GLP-1R expression. Extrathyroidal extension showed positive association with GLP-1R expression that was almost significant. Sex, age, tumor size, and lymph node metastasis were not significantly associated with GLP-1R expression.

Conclusion

Some parts of PTC tissues express GLP-1R, and GLP-1R expression in PTC was negatively correlated with tumor multifocality. The long-term influence of pharmacologically increased GLP-1 on thyroid follicular cells and development and progression of tumors originating from thyroid follicular cells should be investigated.

Citations

Citations to this article as recorded by  
  • Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
    Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho
    Diabetes, Obesity and Metabolism.2024; 26(1): 108.     CrossRef
  • Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
    Giovanni Antonio Silverii, Matteo Monami, Marco Gallo, Alberto Ragni, Francesco Prattichizzo, Valerio Renzelli, Antonio Ceriello, Edoardo Mannucci
    Diabetes, Obesity and Metabolism.2024; 26(3): 891.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
    Ana E. Espinosa De Ycaza, Juan P. Brito, Rozalina G. McCoy, Hui Shao, Naykky Singh Ospina
    Thyroid®.2024;[Epub]     CrossRef
  • Investigation the impact of liraglutide on the thyroid function tests
    Emre URHAN
    Turkish Journal of Clinics and Laboratory.2023; 14(2): 339.     CrossRef
  • GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population
    Rehab S. Abdul-Maksoud, Walid S.H. Elsayed, Nearmeen M. Rashad, Rasha S. Elsayed, Shereen Elshorbagy, Mohamed G. Hamed
    Gene.2022; 834: 146597.     CrossRef
  • Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
    Weiting Hu, Rui Song, Rui Cheng, Caihong Liu, Rui Guo, Wei Tang, Jie Zhang, Qian Zhao, Xing Li, Jing Liu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
    Zheng Yang, Yuhuan Lv, Meng Yu, Mei Mei, Linyu Xiang, Subei Zhao, Rong Li
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume
    Muhammed Erkam Sencar, Davut Sakiz, Murat Calapkulu, Sema Hepsen, Muhammed Kizilgul, Ilknur Unsal Ozturk, Bekir Ucan, Murat Bayram, Busra Betul Cagir, Safak Akin, Mustafa Ozbek, Erman Cakal
    European Thyroid Journal.2019; 8(6): 307.     CrossRef
  • Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine
    Yuejia Song, Min Zhou, Yang Cao, Jiping Qi, Jingshu Geng, Xiaomin Liu
    Oncology Letters.2017; 13(4): 2684.     CrossRef
  • Exendin-4 does not modify growth or apoptosis of human colon cancer cells
    He Wenjing, Yu Shuang, Li Weisong, Xiao Haipeng
    Endocrine Research.2017; : 1.     CrossRef
  • GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
    Takashi Nomiyama, Toshihiko Yanase
    Expert Review of Endocrinology & Metabolism.2016; : 1.     CrossRef
  • Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
    Wenjing He, Shuang Yu, Liantang Wang, Mian He, Xiaopei Cao, Yanbing Li, Haipeng Xiao
    Molecular and Cellular Endocrinology.2016; 436: 240.     CrossRef
  • Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma
    Sebastian Bardosi, Attila Bardosi, Zsuzsanna Nagy, Dora Reglodi
    Journal of Molecular Neuroscience.2016; 60(2): 171.     CrossRef
  • Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes
    Chin-Hsiao Tseng
    Oncotarget.2016; 7(17): 24871.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)
    Min Jung Jung, Su Kyoung Kwon
    Endocrinology and Metabolism.2015; 30(2): 233.     CrossRef
  • Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)
    Daeyoon Park, Eun Kyung Lee
    Endocrinology and Metabolism.2015; 30(2): 231.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism